Trials / Completed
CompletedNCT02333565
Combination of Everolimus and Octreotide LAR in Aggressive Recurrent Meningiomas
Combination of Everolimus and Octreotide LAR in Aggressive Recurrent Meningiomas.
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- Assistance Publique Hopitaux De Marseille · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To determine if combination of everolimus and octreotide exert an anti-tumoral activity in recurrent and/or aggressive meningiomas growth with limited adverse effects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Everolimus | |
| DRUG | Octreotide |
Timeline
- Start date
- 2015-01-22
- Primary completion
- 2019-01-21
- Completion
- 2023-05-24
- First posted
- 2015-01-07
- Last updated
- 2023-05-25
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT02333565. Inclusion in this directory is not an endorsement.